Applications

1172.1 – Testing for BRAF mutation in patients with metastatic melanoma for access to vemurafenib (resubmission)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type Re-application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Testing for BRAF mutation is to identify in tumours obtained from metastatic melanoma patients those that carry the BRAF V600 mutation.

Type: Co-dependent technology

Medical condition this application addresses

Patients with unresectable or metastatic (stage IIIC or stage IV) melanoma

Previous applications

1172 – Testing for BRAF mutation in patients with advanced melanoma for access to vemurafenib

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 31 March 2016